BIOMAT Database Logo BIOMAT Database Logo

[Study of catecholamines and DOPA in obsidan treatment of patients with circulatory insufficiency]. 1979

Z M Kiseleva, and A I Orlova

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D005260 Female Females
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Z M Kiseleva, and A I Orlova
[Cardiotonic activity of L-DOPA in the treatment of patients with chronic circulatory insufficiency].
January 1980, Terapevticheskii arkhiv,
Z M Kiseleva, and A I Orlova
[Plasma ceruloplasmin and excretion of catecholamines in atherosclerotic myocardiosclerosis patients with circulatory insufficiency].
January 1969, Vrachebnoe delo,
Z M Kiseleva, and A I Orlova
[Plasma concentration and urinary excretion of catecholamines in patients with congestive circulatory insufficiency].
November 1972, Kardiologiia,
Z M Kiseleva, and A I Orlova
[Excretion of corticosteroids and catecholamines in atherosclerotic cardiosclerosis with circulatory insufficiency].
November 1967, Vrachebnoe delo,
Z M Kiseleva, and A I Orlova
[Acedoxin treatment of patients with circulatory insufficiency].
September 1968, Kardiologiia,
Z M Kiseleva, and A I Orlova
[Erychroside treatment of patients with circulatory insufficiency].
December 1966, Vrachebnoe delo,
Z M Kiseleva, and A I Orlova
[Treatment of patients with circulatory insufficiency with erysimine].
January 1964, Klinicheskaia meditsina,
Z M Kiseleva, and A I Orlova
[Treatment with periplocin of patients with circulatory insufficiency].
February 1960, Sovetskaia meditsina,
Z M Kiseleva, and A I Orlova
[Long-term ambulatory treatment of patients with circulatory insufficiency].
January 1982, Terapevticheskii arkhiv,
Z M Kiseleva, and A I Orlova
[Cavinton treatment of patients with chronic cerebral circulatory insufficiency].
April 1986, Vrachebnoe delo,
Copied contents to your clipboard!